依鲁替尼抑制慢性淋巴细胞白血病中游离脂肪酸代谢。
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
机构信息
a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , USA.
b Davidoff Cancer Center, Rabin Medical Center , Institute of Hematology, Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel.
出版信息
Leuk Lymphoma. 2018 Nov;59(11):2686-2691. doi: 10.1080/10428194.2018.1439167. Epub 2018 Feb 21.
Abstract
Unlike normal B-cells, and similar to fat cells, chronic lymphocytic leukemia (CLL) cells aberrantly express lipoprotein lipase (LPL), which contributes to free fatty acids (FFAs) metabolism. Here we show that, in CLL cells, the B-cell receptor (BCR) inhibitor ibrutinib reduced LPL mRNA and protein levels and inhibited FFA metabolism . Likewise, in CLL cells from ibrutinib-treated patients, FFA metabolism was reduced and eventually stopped. Because ibrutinib disrupts CLL cells' ability to use FFAs for energy production, and because various BCR-dependent cellular functions rely on a continuous supply of chemical energy, ibrutinib interrupts several pathways imperative for cellular function in CLL cells.
摘要
与正常 B 细胞不同，慢性淋巴细胞白血病（CLL）细胞异常表达脂蛋白脂肪酶（LPL），这有助于游离脂肪酸（FFA）代谢。在这里，我们表明，在 CLL 细胞中，B 细胞受体（BCR）抑制剂伊布替尼降低了 LPL mRNA 和蛋白水平，并抑制了 FFA 代谢。同样，在伊布替尼治疗的 CLL 患者的细胞中，FFA 代谢减少，最终停止。由于伊布替尼破坏了 CLL 细胞利用 FFA 产生能量的能力，并且由于各种 BCR 依赖的细胞功能依赖于化学能量的持续供应，伊布替尼中断了 CLL 细胞中几个对细胞功能至关重要的途径。
相似文献
1
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.依鲁替尼抑制慢性淋巴细胞白血病中游离脂肪酸代谢。
Leuk Lymphoma. 2018 Nov;59(11):2686-2691. doi: 10.1080/10428194.2018.1439167. Epub 2018 Feb 21.
2
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.NOTCH1 活性降低与慢性淋巴细胞白血病对依鲁替尼的反应相关。
Clin Cancer Res. 2019 Dec 15;25(24):7540-7553. doi: 10.1158/1078-0432.CCR-19-1009. Epub 2019 Oct 2.
3
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.依鲁替尼对体内慢性淋巴细胞白血病肿瘤微环境相互作用的破坏——一项研究者发起的II期研究结果
Clin Cancer Res. 2016 Apr 1;22(7):1572-82. doi: 10.1158/1078-0432.CCR-15-1965. Epub 2015 Dec 9.
4
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.在接受依鲁替尼治疗的慢性淋巴细胞白血病中，西妥昔单抗抑制Wnt5a诱导的Rac1激活。
Leukemia. 2017 Jun;31(6):1333-1339. doi: 10.1038/leu.2016.368. Epub 2016 Dec 1.
5
Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.由STAT3驱动的异常LPL表达介导慢性淋巴细胞白血病细胞中的游离脂肪酸代谢。
Mol Cancer Res. 2015 May;13(5):944-53. doi: 10.1158/1541-7786.MCR-14-0412. Epub 2015 Mar 2.
6
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.未突变的慢性淋巴细胞白血病中依赖布鲁顿酪氨酸激酶（BTK）的细胞增殖增强，使其对依鲁替尼的敏感性增加。
Oncotarget. 2016 Jan 26;7(4):4598-610. doi: 10.18632/oncotarget.6727.
7
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.CD69表达可能预测对苯达莫司汀的反应，而依鲁替尼或idelalisib对其的调节可增强慢性淋巴细胞白血病中的细胞毒性作用。
Oncotarget. 2016 Feb 2;7(5):5507-20. doi: 10.18632/oncotarget.6685.
8
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.通过脂蛋白脂肪酶抑制剂奥利司他靶向脂质代谢会导致B细胞慢性淋巴细胞白血病细胞凋亡。
Leukemia. 2008 Mar;22(3):585-92. doi: 10.1038/sj.leu.2405058. Epub 2007 Dec 13.
9
The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.在体外，地塞米松可增强依鲁替尼对B细胞增殖的抑制作用：应用于慢性淋巴细胞白血病。
Leuk Res. 2016 Aug;47:1-7. doi: 10.1016/j.leukres.2016.05.003. Epub 2016 May 10.
10
Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者在短期和长期依鲁替尼治疗期间HLA-DR表达的动态变化。
Leuk Res. 2018 Sep;72:113-119. doi: 10.1016/j.leukres.2018.08.006. Epub 2018 Aug 10.
引用本文的文献
1
Fatty acid metabolism shapes immune responses in chronic lymphocytic leukemia.脂肪酸代谢塑造慢性淋巴细胞白血病中的免疫反应。
Biomark Res. 2025 Mar 12;13(1):42. doi: 10.1186/s40364-025-00753-7.
2
Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage.抑制布鲁顿酪氨酸激酶可限制脑出血后的神经炎症。
Theranostics. 2025 Jan 1;15(2):494-508. doi: 10.7150/thno.101024. eCollection 2025.
3
The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors.慢性淋巴细胞白血病细胞的纳米力学特性与肌动蛋白细胞骨架相关，并且是布鲁顿酪氨酸激酶抑制剂的潜在靶点。
Hemasphere. 2023 Jul 21;7(8):e931. doi: 10.1097/HS9.0000000000000931. eCollection 2023 Aug.
4
Lipotoxicity as a Barrier for T Cell-Based Therapies.脂毒性作为基于 T 细胞疗法的障碍。
Biomolecules. 2022 Aug 25;12(9):1182. doi: 10.3390/biom12091182.
5
Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies.造血作用和血液系统恶性肿瘤中的单细胞代谢组学
Front Oncol. 2022 Jul 13;12:931393. doi: 10.3389/fonc.2022.931393. eCollection 2022.
6
Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.自身免疫性风湿病中的脂质代谢：对现代和传统治疗的影响。
J Clin Invest. 2022 Jan 18;132(2). doi: 10.1172/JCI148552.
7
The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.B 细胞淋巴瘤中 BTK 抑制剂的耐药机制与治疗策略。
Hematol Oncol. 2021 Dec;39(5):605-615. doi: 10.1002/hon.2933. Epub 2021 Oct 15.
8
Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia.载脂蛋白A及基于载脂蛋白A和腺苷脱氨酶的新风险评分系统在慢性淋巴细胞白血病中的预后及治疗价值
Front Oncol. 2021 Jul 1;11:698572. doi: 10.3389/fonc.2021.698572. eCollection 2021.
9
Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma.不同的 BTK 抑制剂可诱导明显不同的细胞凋亡，但对套细胞淋巴瘤的趋化作用和脂质堆积的抑制作用相似。
BMC Cancer. 2021 Jun 26;21(1):732. doi: 10.1186/s12885-021-08475-3.
10
Linking Immunoevasion and Metabolic Reprogramming in B-Cell-Derived Lymphomas.B细胞淋巴瘤中免疫逃逸与代谢重编程的关联
Front Oncol. 2020 Nov 5;10:594782. doi: 10.3389/fonc.2020.594782. eCollection 2020.
本文引用的文献
1
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.依鲁替尼治疗慢性淋巴细胞白血病的药代动力学和药效学评估：低剂量的理论依据。
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1381-1392. doi: 10.1080/17425255.2016.1239717. Epub 2016 Oct 11.
2
Metabolism pathways in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的代谢途径。
Leuk Lymphoma. 2016;57(4):758-65. doi: 10.3109/10428194.2015.1106533. Epub 2015 Dec 8.
3
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.伊布替尼作为慢性淋巴细胞白血病患者的初始治疗方法。
N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.
4
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.依鲁替尼和idelalisib协同靶向套细胞淋巴瘤和慢性淋巴细胞白血病中由BCR控制的黏附：联合治疗的理论依据。
Blood. 2015 Apr 2;125(14):2306-9. doi: 10.1182/blood-2014-12-619163.
5
Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.由STAT3驱动的异常LPL表达介导慢性淋巴细胞白血病细胞中的游离脂肪酸代谢。
Mol Cancer Res. 2015 May;13(5):944-53. doi: 10.1158/1541-7786.MCR-14-0412. Epub 2015 Mar 2.
6
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.依鲁替尼抑制急性髓系白血病中SDF1/CXCR4介导的迁移。
Oncotarget. 2014 Oct 30;5(20):9930-8. doi: 10.18632/oncotarget.2479.
7
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.依鲁替尼抑制BCR和NF-κB信号传导，并减少慢性淋巴细胞白血病患者组织驻留细胞中的肿瘤增殖。
Blood. 2014 May 22;123(21):3286-95. doi: 10.1182/blood-2014-02-548610. Epub 2014 Mar 21.
8
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.BTK 抑制可通过其对 B 细胞受体信号活性的影响来靶向体内 CLL 增殖。
Leukemia. 2014 Mar;28(3):649-57. doi: 10.1038/leu.2013.358. Epub 2013 Nov 25.
9
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.伊布替尼治疗复发慢性淋巴细胞白血病的 BTK 靶点。
N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19.
10
Methylation status regulates lipoprotein lipase expression in chronic lymphocytic leukemia.甲基化状态调节慢性淋巴细胞白血病中的脂蛋白脂肪酶表达。
Leuk Lymphoma. 2013 Aug;54(8):1844-8. doi: 10.3109/10428194.2013.796057. Epub 2013 Jun 21.
Zotero 插件